NEW YORK--(BUSINESS WIRE)--Jan. 24, 2006--Axonyx Inc. (NASDAQ: AXYX) announced today completion of the ascending single dose Phase I trial with Posiphen(TM), in clinical development for the treatment of Alzheimer’s disease progression. This double-blind, placebo controlled study of Posiphen in healthy men and women sought to establish well tolerated doses. Posiphen appears to be well tolerated at single doses up to and including 80mg. Blood levels of Posiphen associated with this study were higher than those associated with beneficial effects on beta-amyloid metabolism in animal models. The build-up of beta-amyloid (A beta) is generally believed to be causative of the dementia of Alzheimer’s disease. No serious adverse events were reported at any dose level.
